There are currently three major classes of ARV drugs: nucleoside or nucleotide analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). The difference between Anti-Retroviral (ARV) and Anti-Retroviral Therapy (ART) is that ARVs are drugs that have suppressive effect on HIV while ART is an anti HIV treatment using a combination of a minimum of at least three ARVs.
No, ARVs are not a cure for AIDS. These drugs suppress HIV viral replication, consequently delaying disease progression, thereby improving immunity and delaying mortality. They prolong and enhance the quality of life of PLWHA, changing a uniformly fatal disease to a manageable chronic illness.
No, an HIV patient should never interrupt taking ARVs for any reasons expect when recommended by the physician. Interruption will cause viral drug resistance resulting in treatment failure. The consequence of non-adherence is the emergence of viral drug resistance. As resistant strains replicate within a patient, ARVs will fail to suppress the virus. There is then the potential of this strain being transmitted within the community and nation, starting an additional epidemic of resistant HIV with very little or no options for treatment. Lack of adherence is the major contributing factor to drug resistance and must be not only the patientï¿½s, but also the nationï¿½s concern.
Yes, HIV positive children can be on ART once their clinical stage is determined by their physician. ART have a markedly positive effect on children, by improving their development and growth. The ARV preparation and dosage for children are different than those of adults, thus children should not be given ARVs prescribed for adults.
Yes, HIV pregnant women can be on ART. Most ARVs are relatively safe, except a couple that are harmful to the fetal development. The physician will prescribe the appropriate ARV drugs for pregnant women.
No, ARVs do not eliminate the transmission of HIV/AIDS. They only suppress virus replication. Therefore, an HIV patient on ART still transmits HIV. Safe sexual practices should always be practiced.
Once a patient starts on ART, the medications must be taken for life near 100% adherence. ARVs only suppress the virus, but do not destroy it. Therefore, the drugs need to be taken all the time to continuously suppress the virus since it will always be in the body.
Clinical and non-clinical eligibility criteria will be used to evaluate if HIV patients should be on ART. HIV patients will initially be evaluated at their nearest health centers. Those who have signs and symptoms of WHO Stage III or AIDS defining illnesses will be referred to Care and Treatment Centres for further evaluation and treatment. Other points of referral for ART services include TB clinics, hospital outpatients and inpatients, antenatal care (ANC) and the Voluntary Counseling and Testing (VCT) center. Once the patients are examined by the ART physicians, hospital level quota, priority for vulnerable groups and the readiness of the patients will be taken into account before ART is started. If a clinically eligible patient is not started on ART as a result of not meeting any of the above non-clinical criteria, the patient will be put on a waiting list for ART and will be continually monitored and treated for other Opportunistic Infections. Patients on ART waiting list must be able to see their providers at any time they feel there is need for evaluation.
This question is best deferred to appropriate caregivers. Side effects could be numerous and relatively common because three different drugs are being administered at the same time. Most of the side effects, however are minor and will be tolerated as patients continue to take the drugs. In rare instances, the side effects could be severe and life threatening requiring medication adjustment or complete discontinuation and change to completely different drug regimen. It is, therefore, highly advisable that patients return to their providers for scheduled visit and close follow up.